van Mourik, Peter http://orcid.org/0000-0001-7999-9635
Michel, Sabine
Vonk, Annelotte M.
Beekman, Jeffrey M.
van der Ent, Cornelis K.
De Keyser, Hilde
Lammertyn, Elise
van Koningsbruggen-Rietschel, Silke
Naehrlich, Lutz
Pool, Judith
van de Craen, Marc
Aguilera, Begoña
Pott, Johanna
Vries, Rob G. J.
Boj, Sylvia F.
De Boeck, Kris
Vermeulen, François
Ramalho, Anabela S.
Silva, Iris A. L.
Amaral, Margarida D.
Goddeeris, Matthew
Gilmartin, Geoffrey
,
Funding for this research was provided by:
Horizon 2020 Framework Programme (Grant agreement no. 755021)
Article History
Received: 31 March 2020
Accepted: 12 May 2020
First Online: 3 June 2020
Ethics approval and consent to participate
: This study was approved by the Medical Research Ethics Committee (METC) of the University Medical Center Utrecht. The study will be performed according to Good Clinical Practice guidelines, and participants will have to sign an informed consent form before they can be included in this study.
: Not applicable.
: CKE reports grants from GSK, Nutricia, TEVA, Gilead, Vertex, ProQR, Proteostasis, Galapagos NV, and grants from Eloxx outside the submitted work and has a patent 10006904 with royalties paid. JMB is inventor on a patent related to CFTR function measurements in organoids and has received financial royalties. He also participates in industry-sponsored clinical trials (Galapagos NV, Vertex Pharmaceuticals, Proteostasis, Eloxx Pharmaceuticals) and received travel reimbursements and speaker’s fees. The other authors have nothing to disclose.